Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Takeaways from AP’s report on potential impacts of Alaska’s proposed Ambler Access Road - 2Vote in favor of your favored spot to peruse
- 3Transcript: Scott Gottlieb on "Face the Nation with Margaret Brennan," Dec. 7, 2025
- 4How to disinfect if the stomach bug hits your home
- 5Wizz CEO: We’re going to invest $1 b. in Israeli market
- Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars
- Ukraine's naval drones are gunning for Russia's 'shadow fleet.' A security source says a tanker just suffered a critical hit.
- The Magnificence of Extraordinariness: Presenting Valuable Adornments and Gemstones
- Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination
- 4 Must-Visit bar-b-que Eateries This Year
- Public Parks in the USA
- The World's Dazzling Regular Miracles
- First Greenland, now Iceland? Annexation joke by Trump ally gets frosty response in the Arctic nation.
- Architect Frank Gehry has died: See his most iconic buildings
